Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention.

NCT01930773 is registered in ClinicalTrials.gov with Medical University of Warsaw as lead sponsor.

NCT NCT01930773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01930773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention.
Lead sponsor
Medical University of Warsaw
Phase
Phase 3
Overall status
Unknown status
Start date
March 31, 2013
Completion date
September 30, 2019
Enrollment
150 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stable angina